Disruption Scan: Corporate Strategy

The challenger brands were small but growing fast, and the board wanted to know whether they were a fad or a structural threat. Internal views split between ignore it and panic. The strategy team wanted an evidence-based read from across the value chain, retailers, former challenger operators and channel experts, before recommending a response.

Client
Global consumer-goods company
Sector
Consumer goods
Engagement
Disruption threat assessment
Timeline
4 weeks
01/

The Challenge

What was at stake

The incumbent had to decide whether to acquire, compete or ignore a rising category. Internal opinion was polarised and no one had independent evidence on the challengers' real durability. The risk was over-reacting to a fad or under-reacting to a structural shift. Both are expensive mistakes at scale.

02/

How We Approached It

4 steps
03/

What We Delivered

3 outputs
04/

Outcome

What it changed
9
Experts
4 weeks
Timeline
Structural vs cyclical
Question
Threat verdict
Output
05/

In Their Words

Anonymised, role-based

Half the room said fad, half said crisis. Nine people across the value chain gave us the evidence to stop arguing and act. It was structural, and we moved.

Chief Strategy Officer
06/

Anonymity & Compliance

How this study was produced

This is a representative, anonymised composite of a typical corporates & strategy engagement. Client identity is removed and the figures illustrate the format and scale of the work. They are not a record of a single named mandate. Every expert call is scoped to general market knowledge, screened for material non-public information before findings reach a deal team, and documented for audit. See our compliance framework for full detail.

07/

Related Case Studies

3 similar
CORP-01
CORPORATE STRATEGY · MARKET ENTRY
Fortune 500 industrial, strategy team

A Fortune 500 strategy team validated a new-geography entry with in-market operators before committing capital.

CORP-02
CORP DEV · ACQUISITION DILIGENCE
Global technology acquirer, corp-dev team

A strategic acquirer tested a target's standalone story and its cross-sell revenue case with expert-led diligence.

VC-05
SERIES A LEAD · HEALTHTECH TEARDOWN
Sector-focused fund, $400M AUM

Before leading a healthtech Series A, a sector fund ran a teardown with the clinicians and buyers who actually evaluate the category.

Running the same decision? Brief us.

Response under 4 hours, Mon–Fri.
Contact Us
© 2026 Growth Insights Limited. All rights reserved.fieldsignalhq.com